Cerep SA names Dr. Markus H. Weissbach CEO of Hesperion

29.09.2006

Hesperion Ltd, a fully-owned subsidiary of Cerep SA, announced the appointment of Dr. Markus H. Weissbach as Chief Executive Officer of Hesperion. Dr. Markus H. Weissbach's new appointment will take effect on Monday October 2, 2006, in replacement of Dr Vincent Charlon, CEO of Hesperion since 1998.

Dr Markus Weissbach is a medical doctor with over 20 years of experience in clinical development, gained within the pharmaceutical and CRO industries. He joined Hesperion in October 2004 as Chief Operating Officer from his previous position of Managing Director and founder of EHCOR GmbH, a consultancy firm for the biotechnology and the CRO industry. Prior to that Dr. Weissbach held several executive positions at the CRO ICON plc. Prior to his time at ICON, Dr. Weissbach held senior management positions in the pharmaceutical industry, at Takeda Euro R&D Center, Frankfurt, Germany (1994-1996) and at Knoll AG, Ludwigshafen, Germany (1986-1994). Between 1982 and 1986 Dr Weissbach worked in intensive care, surgery, cardiology and oncology.

Dr. Weissbach has been a member of the Executive Management Team of Hesperion and acted as deputy CEO since joining the Company. As Chief Operating Officer, Dr Weissbach had direct clinical & regulatory management responsibilities and was particularly instrumental in the development and implementation of Hesperion strategies for company growth, high-quality of services and global expansion with a special focus on Hesperion's development in Central and Eastern Europe.

Dr. Vincent Charlon, the former CEO of Hesperion since the start of its development as the clinical service provider of Actelion Ltd. in 1998, has recently resigned from his position in order to pursue new career opportunities. Dr. Charlon will keep his position on the Board of Directors of Hesperion and will continue to support the Company and Dr Weissbach.

https://www.bionity.com/de/news/58297/cerep-sa-names-dr-markus-h-weissbach-ceo-of-hesperion.html